Department of Oncology and Nuclear Medicine, Sestre Milosrdnice University Hospital Center, Zagreb, Croatia.
School of Dental Medicine, University of Zagreb, Zagreb, Croatia.
Acta Clin Croat. 2022 Oct;61(Suppl 3):51-56. doi: 10.20471/acc.2022.61.s3.7.
Anti-androgen therapy continues to be a basic pilar of treatment for both localized and metastatic prostate cancer. The advent of new generation of androgen receptor targeted agents (ARTA) transformed the care of patients with advanced disease. After such a success, the steps were taken to incorporate a new generation of ARTAs into the treatment landscape of localized prostate cancer. High-risk prostate cancer represents the most aggressive form of localized disease with significant metastatic potential and poor outcome. Here, the impact of novel therapies will likely be profound and transforming. This clinical space has already been a showcase for multidisciplinary treatment where the combination of local therapies with systemic treatment gradually improved patient outcomes and the chances of cure. The most recent step in redefining the treatment of localized disease is the adoption of novel ARTAs moving forward the multidisciplinary platform. In this narrative review, we discuss current clinical evidence supporting the use of novel ARTAs in patients with localized high-risk prostate cancer and cover recent developments in biomarker-driven strategies for treatment individualization in this clinical context.
抗雄激素治疗仍然是局部和转移性前列腺癌治疗的基本支柱。新一代雄激素受体靶向药物（ARTA）的出现改变了晚期疾病患者的治疗方式。在取得如此成功之后，人们采取措施将新一代的 ARTA 纳入局部前列腺癌的治疗方案中。高危前列腺癌是局部疾病中最具侵袭性的形式，具有显著的转移潜力和不良预后。在这里，新疗法的影响可能是深远的和变革性的。这一临床领域已经展示了多学科治疗的成果，局部治疗与全身治疗的结合逐渐改善了患者的结局和治愈的机会。重新定义局部疾病治疗的最新举措是采用新型 ARTA，将多学科平台向前推进。在这篇叙述性综述中，我们讨论了目前支持在局部高危前列腺癌患者中使用新型 ARTA 的临床证据，并介绍了在这种临床情况下，针对治疗个体化的生物标志物驱动策略的最新进展。
